Immunovia AB (publ) (IMMNOV.ST)
SEK 0.27
(1.31%)
SEK 0.27
(1.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 31.69 Million SEK | -44.19% |
| 2022 | 56.78 Million SEK | -5.21% |
| 2021 | 59.9 Million SEK | -3.03% |
| 2020 | 61.77 Million SEK | 0.02% |
| 2019 | 61.76 Million SEK | 300.25% |
| 2018 | 15.43 Million SEK | 10.42% |
| 2017 | 13.97 Million SEK | 106.15% |
| 2016 | 6.77 Million SEK | -12.06% |
| 2015 | 7.7 Million SEK | 146.21% |
| 2014 | 3.13 Million SEK | 23.92% |
| 2013 | 2.52 Million SEK | 51.13% |
| 2012 | 1.67 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 27.32 Million SEK | -13.76% |
| 2024 Q2 | 38.56 Million SEK | 41.1% |
| 2023 Q4 | 31.69 Million SEK | -43.79% |
| 2023 FY | 31.69 Million SEK | -44.19% |
| 2023 Q1 | 58.73 Million SEK | 3.42% |
| 2023 Q2 | 58.83 Million SEK | 0.17% |
| 2023 Q3 | 56.37 Million SEK | -4.18% |
| 2022 FY | 56.78 Million SEK | -5.21% |
| 2022 Q4 | 56.78 Million SEK | -12.02% |
| 2022 Q3 | 64.54 Million SEK | -0.55% |
| 2022 Q2 | 64.9 Million SEK | 3.86% |
| 2022 Q1 | 62.48 Million SEK | 4.31% |
| 2021 Q2 | 75.91 Million SEK | 18.08% |
| 2021 Q3 | 67.38 Million SEK | -11.24% |
| 2021 Q4 | 59.9 Million SEK | -11.1% |
| 2021 FY | 59.9 Million SEK | -3.03% |
| 2021 Q1 | 64.29 Million SEK | 4.08% |
| 2020 Q4 | 61.77 Million SEK | -3.5% |
| 2020 FY | 61.77 Million SEK | 0.02% |
| 2020 Q3 | 64.01 Million SEK | -2.7% |
| 2020 Q2 | 65.79 Million SEK | -0.81% |
| 2020 Q1 | 66.33 Million SEK | 7.41% |
| 2019 Q2 | 56.54 Million SEK | 1.1% |
| 2019 Q1 | 55.92 Million SEK | 262.45% |
| 2019 FY | 61.76 Million SEK | 300.25% |
| 2019 Q4 | 61.76 Million SEK | 7.73% |
| 2019 Q3 | 57.33 Million SEK | 1.39% |
| 2018 Q4 | 15.43 Million SEK | 12.81% |
| 2018 Q2 | 22.86 Million SEK | 58.82% |
| 2018 Q3 | 13.67 Million SEK | -40.18% |
| 2018 FY | 15.43 Million SEK | 10.42% |
| 2018 Q1 | 14.39 Million SEK | 3.04% |
| 2017 Q1 | 7.57 Million SEK | 11.81% |
| 2017 Q2 | 9.76 Million SEK | 28.88% |
| 2017 Q3 | 8.08 Million SEK | -17.19% |
| 2017 Q4 | 13.97 Million SEK | 72.75% |
| 2017 FY | 13.97 Million SEK | 106.15% |
| 2016 Q2 | 5.62 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 6.77 Million SEK | -12.06% |
| 2016 Q4 | 6.77 Million SEK | 0.0% |
| 2015 Q3 | 7.7 Million SEK | 28.28% |
| 2015 Q1 | 6 Million SEK | 91.93% |
| 2015 Q4 | 7.7 Million SEK | 0.0% |
| 2015 FY | 7.7 Million SEK | 146.21% |
| 2015 Q2 | 6 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | 3.13 Million SEK | 0.0% |
| 2014 FY | 3.13 Million SEK | 23.92% |
| 2014 Q3 | 3.13 Million SEK | 0.0% |
| 2013 FY | 2.52 Million SEK | 51.13% |
| 2012 FY | 1.67 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AroCell AB (publ) | 11.24 Million SEK | -181.789% |
| Devyser Diagnostics AB (publ) | 125 Million SEK | 74.648% |
| Prostatype Genomics AB (publ) | 24.54 Million SEK | -29.094% |
| SenzaGen AB | 29.56 Million SEK | -7.177% |
| Spermosens AB | 13.41 Million SEK | -136.263% |